{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:11:50Z","timestamp":1792595510028,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/01199"],"award-info":[{"award-number":["PI14\/01199"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Information about survival by stage in bladder cancer is scarce, as well as about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the distribution of bladder cancer by stage; 2) to determine cancer-specific survival by stage of bladder cancer; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Incident bladder cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with code C67 according to the ICD-O 3rd edition with any behaviour and any histology, except lymphomas and small cell carcinomas. Cases identified exclusively through the death certificate were excluded. We collected the following data: sex; age; date and method of diagnosis; histology according to the ICD-O 3rd edition; T, N, M and stage at the time of diagnosis; and date of follow-up or death. End point of follow-up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Cases with benign or indeterminate behaviour were excluded for the survival analysis. Actuarial and Kaplan-Meier methods and Cox regression models were used for survival analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One thousand nine hundred fourteen cases were identified. 14% were women and 65.4% were 65\u2009years or older. 3.9% had no stage (benign or undetermined behaviour) and 11.5% had unknown stage. After MI, 37.5% were in stage Ta (non-invasive papillary carcinoma), 3.2% in stage Tis (carcinoma in situ), 34.3% in stage I, 11.7% in Stage II, 4.3% in stage III, and 9.0% in stage IV. Survival was 76% at 5\u2009years. Survival by stage: 98% at stage Ta, 90% at stage Tis, 85% at stage I, 45% at stage II, 35% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage, but not sex, were associated with survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Bladder cancer survival vary greatly with stage, among both non-invasive and invasive cases. The percentage of non-invasive cancers is high. Stage, age, and histology are associated to survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08418-y","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T21:02:38Z","timestamp":1623099758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival"],"prefix":"10.1186","volume":"21","author":[{"given":"J.","family":"Ripoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-5264","authenticated-orcid":false,"given":"M.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ameijide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Franch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"5","key":"8418_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386. https:\/\/doi.org\/10.1002\/ijc.29210.","journal-title":"Int J Cancer"},{"key":"8418_CR2","unstructured":"Galceran J, Carulla M, Almela F, Chico M, Marcos AI, Marcos-Gragera R, et al. Oral communication presented at: XLIV Annual Meeting of the Groupe pour l\u2019Epid\u00e9miologie et l\u2019Enregistrement du Cancer dans les Pays de Langue Latine; 2019, 29\u201331 May. Lisbon; 2019."},{"key":"8418_CR3","unstructured":"Mortalidad de c\u00e1ncer en Espa\u00f1a. Instituto de Salud Carlos III. Available at: http:\/\/ariadna.cne.isciii.es\/MapaP\/ [checked the 08 Sept 2019]."},{"key":"8418_CR4","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.ejca.2015.07.028","volume":"51","author":"R Marcos-Gragera","year":"2015","unstructured":"Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999\u20132007: Results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217\u201330.","journal-title":"Eur J Cancer"},{"issue":"10061","key":"8418_CR5","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SSP, Malmstr\u00f6m PU, Choi W, et al. Bladder cancer. Lancet. 2016;388(10061):2796\u2013810. https:\/\/doi.org\/10.1016\/S0140-6736(16)30512-8.","journal-title":"Lancet."},{"issue":"1","key":"8418_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12885-019-5267-3","volume":"19","author":"MJ Al-Husseini","year":"2019","unstructured":"Al-Husseini MJ, Kunbaz A, Saad AM, Santos JV, Salahia S, Iqbal M, et al. Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. BMC Cancer. 2019;19(1):46. https:\/\/doi.org\/10.1186\/s12885-019-5267-3.","journal-title":"BMC Cancer"},{"issue":"3","key":"8418_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.canep.2013.02.002","volume":"37","author":"F Abdollah","year":"2013","unstructured":"Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37(3):219\u201325. https:\/\/doi.org\/10.1016\/j.canep.2013.02.002.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"8418_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1186\/s12885-016-2832-x","volume":"16","author":"BK Andreassen","year":"2016","unstructured":"Andreassen BK, Aagnes B, Gislefoss R, Andreassen M, Wahlqvist R. Incidence and survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014. BMC Cancer. 2016;16(1):799. https:\/\/doi.org\/10.1186\/s12885-016-2832-x.","journal-title":"BMC Cancer"},{"key":"8418_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2018.03.001","volume":"95","author":"BK Andreassen","year":"2018","unstructured":"Andreassen BK, Grimsrud TK, Haug ES. Bladder cancer survival: women better off in the long run. Eur J Cancer. 2018;95:52\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2018.03.001.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8418_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urolonc.2009.07.025","volume":"29","author":"H Wallerand","year":"2011","unstructured":"Wallerand H, Bernhard J-C, Culine S, Ballanger P, Robert G, Reiter RE, et al. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol. 2011;29(1):4\u201311. https:\/\/doi.org\/10.1016\/j.urolonc.2009.07.025.","journal-title":"Urol Oncol"},{"key":"8418_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/CLEP.S129785","volume":"9","author":"AB Pedersen","year":"2017","unstructured":"Pedersen AB, Mikkelsen EM, Cronin-Fenton D, Kristensen N, Pham TM, Pedersen L, et al. Missing data and Mul-tiple imputation in clinical epidemiological research. Clin Epidemiol. 2017;9:157\u201366. https:\/\/doi.org\/10.2147\/CLEP.S129785.","journal-title":"Clin Epidemiol"},{"key":"8418_CR12","doi-asserted-by":"publisher","first-page":"129.26","DOI":"10.1186\/1471-2288-11-129","volume":"11","author":"N Eisemann","year":"2011","unstructured":"Eisemann N, Waldmann A, Katalinic A. Imputation of missing values oftumour stage in population-based cancer registration. BMC Med Res Methodol. 2011;11:129.26.","journal-title":"BMC Med Res Methodol"},{"key":"8418_CR13","unstructured":"Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology (ICD-O), 1st rev., 3rd. Geneva: World Health Organization; 2013. Available at: https:\/\/apps.who.int\/iris\/bitstreZam\/handle\/10665\/96612\/9789241548496%20eng.pdf;jsessionid=7B2E052FBC84832B13B32AC8B483E069?sequence=1 [checked the 05 July 2019]."},{"key":"8418_CR14","volume-title":"TNM classification of malignant tumours","author":"LH Sobin","year":"2011","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Wiley; 2011.","edition":"7"},{"key":"8418_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canep.2018.11.003","volume":"58","author":"MG Parrya","year":"2019","unstructured":"Parrya MG, Sujenthiranb A, Cowlinga TE, Charmanb S, Nossitera J, Aggarwala A, et al. Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions. Cancer Epidemiol. 2019;58:44\u201351. https:\/\/doi.org\/10.1016\/j.canep.2018.11.003.","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"8418_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377\u201399. https:\/\/doi.org\/10.1002\/sim.4067.","journal-title":"Stat Med"},{"key":"8418_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987. https:\/\/doi.org\/10.1002\/9780470316696."},{"key":"8418_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.canep.2016.01.001","volume":"41","author":"M Ramos","year":"2016","unstructured":"Ramos M, Montano J, Esteva M, et al. Colorectal cancer survival by stage of cases diagnosed in Mallorca, Spain, between 2006 and 2011 and factors associated with survival. Cancer Epidemiol. 2016;41:63\u201370. https:\/\/doi.org\/10.1016\/j.canep.2016.01.001.","journal-title":"Cancer Epidemiol"},{"key":"8418_CR19","unstructured":"Ederer F, Heise H. The effect of eliminating deaths from c\u00e1ncer on general population survival rates. Methodological Note No, 11, End Results Evaluation Section. National Cancer Institute; 1959."},{"key":"8418_CR20","unstructured":"EUROCARE web. Available at: https:\/\/w3.iss.it\/site\/EU5Results\/forms\/SA0007.aspx [checked the 23 Dec 2019]."},{"key":"8418_CR21","first-page":"196","volume":"135","author":"K Damgaard","year":"2013","unstructured":"Damgaard K, Bray F, Moller B. A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer. 2013;135:196\u2013203.","journal-title":"Int J Cancer"},{"issue":"9","key":"8418_CR22","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1002\/cam4.1706","volume":"7","author":"N Makkar","year":"2018","unstructured":"Makkar N, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. Cancer Med. 2018;7(9):4773\u201380. https:\/\/doi.org\/10.1002\/cam4.1706.","journal-title":"Cancer Med"},{"issue":"29","key":"8418_CR23","doi-asserted-by":"publisher","first-page":"48263","DOI":"10.18632\/oncotarget.17593","volume":"8","author":"Q Chen","year":"2017","unstructured":"Chen Q, Li L, Wang G, Hu J, Sun T, Fu B. Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis. Oncotarget. 2017;8(29):48263\u201371. https:\/\/doi.org\/10.18632\/oncotarget.17593.","journal-title":"Oncotarget."},{"key":"8418_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/tau.2018.11.06","volume":"8","author":"K Bilski","year":"2018","unstructured":"Bilski K, Zapa\u0142a \u0141, Skrzypczyk MA, Oszczud\u0142owski M, Dobruch J. Review on gender differences in non-muscle invasive bladder cancer. Transl Androl Urol. 2018;8:12\u201320.","journal-title":"Transl Androl Urol"},{"issue":"2","key":"8418_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","volume":"69","author":"J Dobruch","year":"2016","unstructured":"Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology and outcomes. Eur Urol. 2016;69(2):300\u201310. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.037.","journal-title":"Eur Urol"},{"issue":"5","key":"8418_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/MOU.0000000000000198","volume":"25","author":"I Wolff","year":"2015","unstructured":"Wolff I, Brookman-May S, May M. Sex difference in presentation and outcomes of bladder cancer: biological reality of statistical fluke? Curr Opin Urol. 2015;25(5):418\u201326. https:\/\/doi.org\/10.1097\/MOU.0000000000000198.","journal-title":"Curr Opin Urol"},{"issue":"3","key":"8418_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10552-012-0141-5","volume":"24","author":"S Eloranta","year":"2013","unstructured":"Eloranta S, Adolfsson J, Lambert PC, Stattin P, Akre O, Andersson TML, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24(3):505\u201315. https:\/\/doi.org\/10.1007\/s10552-012-0141-5.","journal-title":"Cancer Causes Control"},{"key":"8418_CR28","doi-asserted-by":"crossref","unstructured":"Andreassen BK, Myklebust TA, Haug ES. Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary\u00a0bladder in Norway. Scand J Urol. 2017;51(1):38\u201343.","DOI":"10.1080\/21681805.2016.1271354"},{"issue":"04","key":"8418_CR29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.4149\/neo_2016_420","volume":"63","author":"S Poletajew","year":"2016","unstructured":"Poletajew S, Biernacki R, Buraczynski P, Chojnacki J, Czarniecki S, Gajewska D, et al. Stage of bladder cancer in Central Europe \u2013 polish perspective. Neoplasma. 2016;63(04):642\u20137. https:\/\/doi.org\/10.4149\/neo_2016_420.","journal-title":"Neoplasma."}],"updated-by":[{"DOI":"10.1186\/s12885-021-08694-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08418-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08418-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T07:03:07Z","timestamp":1629961387000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08418-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8418"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08418-y","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12885-021-08694-8","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-021-08694-8","URL":"https:\/\/doi.org\/10.1186\/s12885-021-08694-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Balearic Islands on the 23rd July 2014. (IB 2363\/14), who authorized us to access to Mallorca Cancer Registry raw data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare that we have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"676"}}